<DOC>
	<DOC>NCT00239460</DOC>
	<brief_summary>The objective of this study is to evaluate the effect of inhaled tiotropium bromide on trough FEV1 and to assess the cardiac effects through 12-lead and Holter ECG monitoring in patients with COPD.</brief_summary>
	<brief_title>Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>History of COPD, FEV1 less than or equal to 65%, FEV1/FVC less than or equal 70% Smoking history greater than or equal to 10 pack years Not history of clinical diagnosis of asthma and/or atopy A history of thoracotomy with pulmonary resection Patients requiring the use of supplemental oxygen therapy for &gt;12 hours per day Chronic use of systemic corticosteroids in an unstable daily dose Patients with a recent history of myocardial infarction A known hypersensitivity to anticholinergic drugs</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>